Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
As part of the PMGDisha-CoWIN integration, Mercer | Mettl has aggregated the database of 5 crore Aadhaar-authenticated and registered candidates, which is now being utilized to deliver vaccinations to the last mile populace
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Employees of QubeHealth’s corporate clients draw as much money as they need to instantly pay for any medical emergencies or regular healthcare payments
The acquisition expands the company’s service portfolio in the transition care segment
Subscribe To Our Newsletter & Stay Updated
